Journal ArticleDOI
Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis.
Bogdan Balas,Renata Belfort,Stephen A. Harrison,Celia Darland,Joan Finch,Steven Schenker,Amalia Gastaldelli,Amalia Gastaldelli,Kenneth Cusi,Kenneth Cusi +9 more
TLDR
Six months of pioglitazone treatment in patients with NASH is associated with weight gain that is attributable to an increase in adipose tissue mass and not to water retention.About:
This article is published in Journal of Hepatology.The article was published on 2007-10-01. It has received 77 citations till now. The article focuses on the topics: Pioglitazone & Weight gain.read more
Citations
More filters
Journal ArticleDOI
Randomized, Placebo-Controlled Trial of Pioglitazone in Nondiabetic Subjects With Nonalcoholic Steatohepatitis
Guruprasad P. Aithal,James Thomas,Philip Kaye,Adam Lawson,Stephen D. Ryder,Ian Spendlove,Andrew Austin,Jan G. Freeman,Linda Morgan,Jonathan Webber +9 more
TL;DR: Pioglitazone therapy over a 12-month period in nondiabetic subjects with NASH resulted in improvements in metabolic and histologic parameters, most notably liver injury and fibrosis.
Journal ArticleDOI
Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies.
TL;DR: This Review highlights novel concepts related to diagnosis, risk prediction, and treatment of non-alcoholic fatty liver disease that could contribute to the development of a multidisciplinary approach for endocrinologists and hepatologists working together in the management of NAFLD.
Journal ArticleDOI
Molecular Mechanisms and Therapeutic Targets in Steatosis and Steatohepatitis
Nora Anderson,Jürgen Borlak +1 more
TL;DR: The contribution of cytokines and other signaling molecules, as well as activity of nuclear receptors, lipids, transcription factors, and endocrine mediators toward cellular dysfunction and progression of steatotic liver disease to NASH is specifically addressed, as is the cross-talk of different cell types in the pathogenesis of NAFLD.
Journal ArticleDOI
Nonalcoholic Fatty Liver Disease: A Review and Update
TL;DR: Currently, therapeutic options for NAFLD are limited to medications that reduce risk factors, but the future holds promise for therapies that might slow the progression of this increasingly prevalent disorder.
Journal ArticleDOI
It's not how fat you are, it's what you do with it that counts.
Samuel Virtue,Antonio Vidal-Puig +1 more
TL;DR: The evidence for an emerging hypothesis that attributes metabolic complications not to obesity per se, but to an individual's capacity for adipose tissue expandability is explored.
References
More filters
Journal ArticleDOI
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.
John A. Dormandy,Bernard Charbonnel,David Eckland,Erland Erdmann,Massimo Massi-Benedetti,Ian K. Moules,Allan M. Skene,Meng H. Tan,P. J. Lefebvre,Gordon D Murray,Eberhard Standl,Robert G. Wilcox,Lars Wilhelmsen,John Betteridge,Kåre I. Birkeland,Alain Golay,Robert J. Heine,László Korányi,Markku Laakso,Marián Mokáň,Antanas Norkus,Valdis Pirags,Toomas Podar,André Scheen,Werner A. Scherbaum,Guntram Schernthaner,Ole Schmitz,Jan Škrha,Ulf Smith,Jan Tatoň +29 more
TL;DR: Overall safety and tolerability was good with no change in the safety profile of pioglitazone identified; mortality rates from heart failure did not differ between groups.
Journal ArticleDOI
Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity
Jeffrey D. Browning,Lidia S. Szczepaniak,Robert L. Dobbins,Pamela Nuremberg,Jay D. Horton,Jonathan Cohen,Scott M. Grundy,Helen H. Hobbs +7 more
TL;DR: The prevalence of hepatic steatosis was greater in men than women among whites, but not in blacks or Hispanics, and significant ethnic and sex differences in the prevalence may have a profound impact on susceptibility to Steatosis‐related liver disease.
Journal ArticleDOI
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Steven E. Kahn,Steven M. Haffner,Heise Ma,William H. Herman,Rury R. Holman,Nigel P. Jones,Barbara G. Kravitz,John M. Lachin,O'Neill Mc,Bernard Zinman,Giancarlo Viberti +10 more
TL;DR: The potential risks and benefits, the profile of adverse events, and the costs of these three drugs should all be considered to help inform the choice of pharmacotherapy for patients with type 2 diabetes.
Journal ArticleDOI
Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome
Giulio Marchesini,Elisabetta Bugianesi,Gabriele Forlani,Fernanda Cerrelli,Marco Lenzi,R. Manini,S. Natale,Ester Vanni,Nicola Villanova,Nazario Melchionda,Mario Rizzetto +10 more
TL;DR: The presence of multiple metabolic disorders is associated with a potentially progressive, severe liver disease and the increasing prevalence of obesity, coupled with diabetes, dyslipidemia, hypertension, and ultimately the metabolic syndrome puts a very large population at risk of forthcoming liver failure in the next decades.
Journal ArticleDOI
Densitometric analysis of body composition: revision of some quantitative assumptions*
TL;DR: It is shown that in a system consisting of two additive components which are mixed but the densities of which are known, the determination of the density of the system allows one to calculate the proportional masses of the two components.
Related Papers (5)
A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis
Renata Belfort,Stephen A. Harrison,Kenneth A. Brown,Celia Darland,Joan Finch,Jean Hardies,Bogdan Balas,Amalia Gastaldelli,Amalia Gastaldelli,Fermin O. Tio,Joseph P. Pulcini,Rachele Berria,Jennie Z. Ma,Sunil Dwivedi,Russell Havranek,Chris Fincke,Ralph A. DeFronzo,George A. Bannayan,Steven Schenker,Kenneth Cusi +19 more
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Steven E. Nissen,Kathy Wolski +1 more
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.
John A. Dormandy,Bernard Charbonnel,David Eckland,Erland Erdmann,Massimo Massi-Benedetti,Ian K. Moules,Allan M. Skene,Meng H. Tan,P. J. Lefebvre,Gordon D Murray,Eberhard Standl,Robert G. Wilcox,Lars Wilhelmsen,John Betteridge,Kåre I. Birkeland,Alain Golay,Robert J. Heine,László Korányi,Markku Laakso,Marián Mokáň,Antanas Norkus,Valdis Pirags,Toomas Podar,André Scheen,Werner A. Scherbaum,Guntram Schernthaner,Ole Schmitz,Jan Škrha,Ulf Smith,Jan Tatoň +29 more